We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Vivus grants Menarini marketing rights to Spedra in Europe, Australia, and New Zealand
07 Oct 2016
Executive Summary
Menarini Group has received rights to market Vivus Inc.’s (focused on sexual health and metabolic and respiratory conditions) Spedra (avanafil) in over 40 European countries, Australia, and New Zealand. Spedra is a phosphodiesterase-5 inhibitor that was approved in the US in early 2012 (as Stendra) and in Europe last month for erectile dysfunction.
Deal Industry
Biotechnology
Pharmaceuticals
Deal Status
Final
Deal Type
Alliance
Manufacturing or Supply
Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?